As a pioneer in the field of liposome development, Creative Biolabs has accumulated over a decade of experience, enabling us to offer a diverse range of drug-loaded liposomes to cater to your varied therapeutic needs. Our products are effective with consistent lot-lot characteristics, uniform particle size, and high encapsulation efficiency to address your challenges in delivering poorly soluble drugs, enhancing drug stability, and achieving sustained release.
Liposomes consist of phospholipids, essential components found in cellular membranes. This gives liposome membranes a phospholipid bilayer structure that closely resembles biological membranes, enabling them to mimic natural cell membranes and interact with mammalian cells, thereby facilitating efficient cellular uptake. Furthermore, liposomes possess attributes of biocompatibility, biodegradability, non-toxicity, and nonimmunogenicity, thereby endowing them with potent and versatile drug delivery capabilities. The encapsulation of drugs within liposomes not only enhances and prolongs their therapeutic effects but also safeguards them against enzymatic degradation, chemical and immunological inactivation, as well as rapid clearance from plasma. This encapsulation strategy minimizes the risk of exposure to healthy tissues, thereby mitigating adverse effects associated with free drugs.
If you require additional functionalities such as targeted delivery and prolonged circulation for drug-loaded liposomes, we offer a range of conjugating services for antibodies, proteins, peptides, and ligands. Furthermore, if you are interested in environmentally responsive liposomes, we can achieve controlled drug release in response to specific stimuli such as enzymes, light, pH, temperature, ultrasound, and more. Feel free to contact us without delay for a tailored program that aligns more closely with your research requirements.
Cat | Product name | Lipid Composition | Data sheet | MSDS | Inquiry |
---|---|---|---|---|---|
LDLY-0724-LD3 | Alendronate Liposome (Anionic) | Soy PC, Cholesterol, Phosphatidylglycerol | Inquiry | ||
LDLY-0724-LD4 | Control Alendronate Liposome (Anionic) | Soy PC, Cholesterol, Phosphatidylglycerol | Inquiry | ||
LDLY-0724-LD5 | DOPG:Chol:PEG2000-ATP Liposome (PEGylated) | DOPG, Cholesterol, 18:0 PEG(2000) PE | Inquiry | ||
LDLY-0724-LD6 | DOPG:DOPC:Chol:PEG2000-ATP Liposome (PEGylated) | DOPG, DOPC, Cholesterol, 18:0 PEG(2000) PE | Inquiry | ||
LDLY-0724-LD15 | PS:Chol:PEG2000-ATP Liposome (PEGylated) | Soy PS, Cholesterol, 18:1 PEG (2000) PE | Inquiry | ||
LDLY-0724-LD16 | PS:PC:Chol:PEG2000-ATP Liposome (PEGylated) | Soy PS, Soy PC, Cholesterol, 18:1 PEG (2000) PE | Inquiry | ||
LDLY-0724-LD25 | PC:Chol:PEG2000-ATP Liposome (PEGylated) | Soy PC, Cholesterol, 18:1 PEG (2000) PE | Inquiry | ||
LDLY-0724-LD26 | DOTAP:Chol:PEG2000-ATP Liposome (PEGylated) | DOTAP, Cholesterol, 18:0 PEG(2000) PE | Inquiry | ||
LDLY-0724-LD27 | DOTAP:DOPC:Chol:PEG2000-ATP Liposome (PEGylated) | DOTAP, DOPC, Cholesterol, 18:0 PEG(2000) PE | Inquiry | ||
LDLY-0724-LD36 | DOPG:Chol-ATP Liposome | DOPG, Cholesterol | Inquiry | ||
LDLY-0724-LD37 | DOPG:DOPC:Chol-ATP Liposome | DOPG, DOPC, Cholesterol | Inquiry | ||
LDLY-0724-LD47 | PS-ATP Liposome | Soy PS | Inquiry | ||
LDLY-0724-LD48 | PS:PC-ATP Liposome | Soy PS, Soy PC | Inquiry | ||
LDLY-0724-LD56 | PC-ATP Liposome | Soy PC | Inquiry | ||
LDLY-0724-LD57 | PC:Chol-ATP Liposome | Soy PC, Cholesterol | Inquiry |
Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
Author: Ghaferi, Mohsen, et al.
This study explored the therapeutic effects of liposomes encapsulating doxorubicin (DOX) and carboplatin (CB) on glioblastoma. Using reverse-phase evaporation, researchers created co-delivery of DOX and CD liposomes (PEGylated and non-PEGylated). These liposomes were utilized in the glioblastoma rat model, which was established by rat glioma C6 cells. The study assessed the rats' survival time, weight changes, serum levels of blood urea nitrogen (BUN), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine. Results indicated that PEGylated liposomes led to lower increase in serum levels of BUN, AST, ALT, and creatinine than non-PEGylated liposomes. This could be attributed to PEG improving the stability of liposomes in the circulation, resulting in prolonged drug release. This study demonstrates that PEGylated liposomes have stronger therapeutic effects on glioblastoma than non-PEGylated liposomes. Moreover, PEGylated liposomes serve as an effective drug delivery platform for co-delivery.
Fig.1 Weight changes and serum concentrations of ALT, AST, BUN and creatinine in rats with glioblastoma.1,2
References
Online Inquiry